<i>TP53</i> co-mutations as an independent prognostic factor in 2nd and further line therapy-<i>EGFR</i> mutated non-small cell lung cancer IV patients treated with osimertinib.

导出 LinkOut

翻译打印收藏纠错

第一作者： Julia,Roeper

第一单位： Department of Internal Medicine-Oncology, Carl v. Ossietzky University of Oldenburg, Pius-Hospital, Oldenburg, Germany.;Department of Hematology and Oncology, Pius-Hospital, Oldenburg, Germany.;Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany.

作者： Julia,Roeper ^[1] ; Petros,Christopoulos ^[2] ; Markus,Falk ^[3] ; Lukas C,Heukamp ^[3] ; Markus,Tiemann ^[3] ; Albrecht,Stenzinger ^[4] ; Michael,Thomas ^[2] ; Frank,Griesinger ^[1]

作者单位： Department of Internal Medicine-Oncology, Carl v. Ossietzky University of Oldenburg, Pius-Hospital, Oldenburg, Germany.;Department of Hematology and Oncology, Pius-Hospital, Oldenburg, Germany.;Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany. ^[1] Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany.;Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), University Hospital, Heidelberg, Germany. ^[2] Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany.;Hematopathology Hamburg, Hamburg, Germany. ^[3] Department of General Pathology and Pathological Anatomy, University Hospital, Heidelberg, Germany. ^[4]

关键词 EGFR Non-small cell lung cancer (NSCLC)Osimertinib TP53 co-mutation metastatic

DOI 10.21037/tlcr-21-754

PMID 35242623

发布时间 2022-05-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Translational lung cancer research

2022年11卷1期

4-13页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

<i>TP53</i> co-mutations as an independent prognostic factor in 2nd and further line therapy-<i>EGFR</i> mutated non-small cell lung cancer IV patients treated with osimertinib.

Translational lung cancer research

相似文献

Translational lung cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

<i>TP53</i> co-mutations as an independent prognostic factor in 2nd and further line therapy-<i>EGFR</i> mutated non-small cell lung cancer IV patients treated with osimertinib.

Translational lung cancer research

相似文献

Translational lung cancer research

相关期刊

检索历史清除